Assay for the simultaneous detection of the *1C and *1F alleles of the CYP1A2 gene by real-time polymerase chain reaction and melting curve analysis

Psychiatric Genetics

Volumn 16, Issue 2, 2006, Pages 81-83

  Casley, William L ^a   LeBlanc Westwood, Carole A ^a  

^a Banting Research Centre   (Canada)

Author keywords

Assay; CYP1A2; Genotype; Pharmacogenetics; Polymerase chain reaction

Indexed keywords

CYTOCHROME P450 1A2; FLUORESCENT DYE; CYTOCHROME P450 1A1; DNA; NEUROLEPTIC AGENT;

ALLELE; ALLELISM; ANALYTIC METHOD; ARTICLE; ASSAY; GENOTYPE; HYBRIDIZATION; MELTING CURVE ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; COMPUTER SYSTEM; DNA DENATURATION; DRUG RESISTANCE; EVALUATION; GENETICS; HEAT; HUMAN; METHODOLOGY; POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; SMOKING;

ALLELES; ANTIPSYCHOTIC AGENTS; COMPUTER SYSTEMS; CYTOCHROME P-450 CYP1A1; DNA; DRUG RESISTANCE; GENOTYPE; HEAT; HUMANS; NUCLEIC ACID DENATURATION; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; REPRODUCIBILITY OF RESULTS; SCHIZOPHRENIA; SENSITIVITY AND SPECIFICITY; SMOKING;

EID: 33646840888     PISSN: 09558829     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ypg.0000185030.35558.6d     Document Type: Article

References (17)

1. Aitchison KJ, Jann MW, Zhao JH, Sakai T, Zaher H, Wolff K, et al. (2000). Clozapine pharmacokinetics and pharmacodynamics studied with Cyp1a2-null mice. J Psychopharmacol 14:353-359.
2. Basile VS, Ozdemir V, Masellis M, Walker ML, Meltzer HY, Lieberman JA, et al. (2000). A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5:410-417.
3. Bernard PS, Lay MJ, Wittwer CT (1998). Integrated amplification and detection of the C677T point mutation in the methylenetetrahydrofolate reductase gene by fluorescence resonance energy transfer and probe melting curves. Anal Biochem 255:101-107.
4. Bertilsson J, Carrillo JA, Dahl ML, Llerena A, Alm C, Bondesson U, et al. (1994). Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38:471-473.
5. Bondolfi G, Morel F, Crettol S, Rachid F, Baumann P, Eap CB (2005). Increased Clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539-543.
6. Chong SA, Tan EC, Tan CH, Mythily S (2003). Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychitry Neurosci 28:185-189.
7. Corchero J, Pimprale S, Kimura S, Gonzalez FJ (2001). Organization of the CYP1A cluster on human chromosome 15: implications for gene regulation. Pharmacogenetics 11:1-6.
8. Dahl ML (2003). Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 41:453-470.
9. Ingelman-Sundberg M, Daly AK, Nebert DW (2005). Human Cytochrome P450 Allele Nomenclature Committee. www.imm.ki.se/CYPalleles/cyp1a2.htm
10. Matsumoto C, Ohmori O, Shinkai T, Hori H, Nakamura J (2004). Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychitar Genet 14:209-213.
11. Nakajima M, Yokoi T, Mizutani M, Kinoshita M, Funayama M, Kamataki T (1999). Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 125:803-808.
12. Ring BJ, Catlow J, Lindsay TJ, Gillespie T, Roskos LK, Cerimele BJ, et al. (1996). Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276:658-666.
13. Sachse C, Brockmoller J, Bauer S, Roots I (1999). Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47:445-449.
14. Schulze TG, Schumacher J, Muller DJ, Krauss H, Alfter D, Maroldt A, et al. (2001). Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 105:498-501.
15. Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Mukit SR, Shriharsh V, et al. (2005). Genetic susceptibility to Tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenom J 5:60-69.
16. Todesco L, Torok M, Krahenbuhl S, Wenk M (2003). Determination of -3858G >A and -164C >A genetic polymorphisms of CYP1A2 in blood and saliva by rapid allelic discrimination: large difference in the prevalence of the -3858G >A mutation between Caucasians and Asians. Eur J Clin Pharmacol 59:343-346.
17. Van der Weide J, Steijns LS, Van Weelden MJ (2003). The effect of smoking and cytochrome P450 CYP1A2 genetic polymorphism on clozapine clearance and dose requirement. Pharmacogenetics 13:169-172.